Evidence map›Paper›PMID 32034430›Full record

ArticleEuropean journal of clinical pharmacology2020

Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study.

Haruhiko Yamazaki, Tomoyuki Yokose, Hiroyuki Hayashi, Hiroyuki Iwasaki, Sachie Osanai, Nobuyasu Suganuma, Hirotaka Nakayama, Katsuhiko Masudo, Yasushi Rino, Munetaka Masuda

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Haruhiko YamazakiDepartment of Breast and Endocrine Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahiku, Yokohama City, Kanagawa, Japan. paruo0413@gmail.com.ORCID http://orcid.org/0000-0002-6640-3529
Tomoyuki YokoseDepartment of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahiku, Yokohama City, Kanagawa, Japan.
Hiroyuki HayashiDepartment of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahiku, Yokohama City, Kanagawa, Japan.
Hiroyuki IwasakiDepartment of Breast and Endocrine Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahiku, Yokohama City, Kanagawa, Japan.
Sachie OsanaiDepartment of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahiku, Yokohama City, Kanagawa, Japan.
Nobuyasu SuganumaDepartment of Breast and Endocrine Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahiku, Yokohama City, Kanagawa, Japan.
Hirotaka NakayamaDepartment of Surgery, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawaku, Yokohama City, Kanagawa, Japan.
Katsuhiko MasudoDepartment of Breast and Thyroid Surgery, Yokohama City University Medical Center, 4-57 Urafunecho, Minamiku, Yokohama City, Kanagawa, Japan.
Yasushi RinoDepartment of Surgery, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawaku, Yokohama City, Kanagawa, Japan.
Munetaka MasudaDepartment of Surgery, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawaku, Yokohama City, Kanagawa, Japan.
Kanagawa Prefectural Hospital Organization · JPYokohama City University · JPYokohama City University Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFibroblast growth factor receptor 4 (FGFR4) expression has association with tumor malignancy. In thyroid cancers, FGFR4 has been reported to be characteristically expressed in aggressive thyroid tumors, such as anaplastic thyroid carcinoma (ATC).

methodsWe investigated FGFR4 expression in patients with ATC and analyzed their clinical responses to lenvatinib. Primary tumor samples were obtained from 12 patients with ATC who underwent surgery or core needle biopsy. FGFR4 protein expression in all ATC samples was analyzed via immunohistochemistry, and the treatment efficacy of lenvatinib was evaluated.

resultsThe proportion of FGFR4-positive cells in the samples ranged from 0 to 50%. Four patients had partial responses, and three patients had stable diseases as a best clinical response to lenvatinib. The median PFS durations of patients with none, weak, and moderate intensity were 0.5, 3.2 (95% CI 1.1-not estimable [NE]), and 4.6 (95% CI 1.1-NE) months, respectively (p = 0.003).

conclusionsBecause FGFR4 was expressed in ATC tissues, the FGFR4 expression might be associated with the treatment efficacy of lenvatinib in a part of ATC patients. To clarify whether FGFR4 can serve as a prognostic or predictive factor for lenvatinib therapy, more cases must be accumulated.

Indexed as

AgedAged, 80 and overAntineoplastic AgentsCohort StudiesFemaleHumansMaleMiddle AgedPhenylurea CompoundsPilot ProjectsQuinolinesReceptor, Fibroblast Growth Factor, Type 4Thyroid Carcinoma, AnaplasticTreatment OutcomeAntineoplastic AgentsFGFR4 protein, humanlenvatinibPhenylurea CompoundsQuinolinesReceptor, Fibroblast Growth Factor, Type 4Clinical researchFibroblast growth factor receptorLenvatinibMolecular biologyThyroid cancer

Identifiers

PMID32034430
OpenAlexW3004519161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.